Britain’s AstraZeneca has been considering “the biggest pharmaceuticals deal in history”, says Max Nisen on Bloomberg: merging with US peer Gilead Sciences to create a company with a market value of $240bn. The aim would be to combine AstraZeneca’s “enviable” drug pipeline with Gilead’s profitable HIV drug business, which has given it a “steady cash flow” and “strong balance sheet”.
Any merger with Gilead would be a bad mistake, says Ben Marlow in The Daily Telegraph. Not only is there “overwhelming” evidence that most mega-mergers end up destroying value, but the ongoing travel restrictions also mean that this one could “take several years to be negotiated”. In any case, with AstraZeneca at the forefront of developing a coronavirus vaccine as well as various treatments for those already infected with the disease, it needs to “concentrate on the day job”. The last thing managers should be doing is “wasting time” with “desktop empire-building”.Tentative talks seem to have gone nowhere, says Nils Pratley in The Guardian. Still, the fact that the idea was even broached at all will unnerve shareholders “who thought the future for the next few years was mapped out and rosy”.
With new cancer drug sales “soaring [and the]cardiovascular and respiratory divisions [ready] to deliver the next round of growth”, AstraZeneca’s CEO Pascal Soriot (pictured) should stick with his current strategy. Instead, he apparently dreams of “signing off in dreaded transformative style” with a deal that could prove “messy and political”.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
-
Bitcoin price one of the most-asked questions on Alexa - here's how to buy the cryptocurrencyAccording to figures from Amazon, which cover September 2023 to November 2024, pop star Taylor Swift and Bitcoin were named among the most popular Alexa queries of 2024
-
Investing for children this Christmas – five ideasIt might not come with a shiny ribbon, but an investment fund could be the gift that keeps on giving. We share five ideas if you are investing for children this Christmas.
-
Halifax: House price slump continues as prices slide for the sixth consecutive monthUK house prices fell again in September as buyers returned, but the slowdown was not as fast as anticipated, latest Halifax data shows. Where are house prices falling the most?
-
Rents hit a record high - but is the opportunity for buy-to-let investors still strong?UK rent prices have hit a record high with the average hitting over £1,200 a month says Rightmove. Are there still opportunities in buy-to-let?
-
Pension savers turn to gold investmentsInvestors are racing to buy gold to protect their pensions from a stock market correction and high inflation, experts say
-
Where to find the best returns from student accommodationStudent accommodation can be a lucrative investment if you know where to look.
-
Best investing appsLooking for an easy-to-use app to help you start investing, keep track of your portfolio or make trades on the go? We round up the best investing apps
-
The world’s best bargain stocksSearching for bargain stocks with Alec Cutler of the Orbis Global Balanced Fund, who tells Andrew Van Sickle which sectors are being overlooked.
-
Revealed: the cheapest cities to own a home in BritainNew research reveals the cheapest cities to own a home, taking account of mortgage payments, utility bills and council tax
-
UK recession: How to protect your portfolioAs the UK recession is confirmed, we look at ways to protect your wealth.
